# Author Index

VOLUME 29, 2003

*Note: Numbers preceded by S1 indicate pages in Volume 29, Supplement 1.*


Abu-Hajir, Majed, 309
Adix, Leah, 595
Albisetti, Manuela, 339
Aharon, Anat, 175
Aledort, Louis M., 55
Anderson, Frederick A., 235
Astermark, Jan, 77

Barbui, Tiziano, 195
Barlogie, Bart, 275
Baronzio, Gianfranco, 489
Baskurt, Oguz K., 435
Berntorp, Erik, 5
BI 51.017 Study Group, 645
Blanchette, Victor S., 605
Blumenfeld, Zeev, 213
Bombardieri, Stefano, 473
Brenner, Benjamin, 121, 165, 175
Bril, Wendy S., 61
Buchanan, George R., 595
Büller, Harry R., S1:37

Carcao, Manuel, 605
Chan, Anthony K.C., 425
Clark, Peter, 155
Conard, Jacqueline, 121, 131

Deitcher, Steven R., 247
Della Rossa, Alessandra, 473
deVeber, Gabrielle, 567

Ebina, Yasuhiko, 639
Eldor, Amiram, 185

Fijnvandraat, Karin, 61
Fink, Louis, 275
Fischer, Kathlelijn, 49
Freitas, Isabel, 489
Fujimoto, Seiichiro, 653

Galli, Monica, 195
Gerhardt, Andrea, 143
Goldhaber, Samuel Z., S1:23
Golomb, Meredith R., 415
Goodeve, Anne C., 23
Grafenhofer, Helga, 633
Greer, Ian A., 155
Griesshammer, Martin, 205
Grünewald, Martin, 205
Günther, Gudrun, 405

Haas, Sylvia, S1:1, S1:17
Hata, Akira, 653
Heilmann, Lothar, 499
Hellgren, Margaretam 125
High, Katherine A., 107
Hip and Knee Registry Investigators, 235
Hommel, Gerhard, 499
Horellou, Marie-Hélène, 131

Ikenoue, Tsuyomu, 645
Inbal, Aida, 171
Israels, Sara J., 363

Journeycake, Janna M., 595

Kajiwara, Yayoi, 645
Kakkar, Ajay K., S1:1, S1:13
Kasper, Carol K., 585
Kato, Emi H., 639
Kaushal, Varsha, 301
Kilcoyne, Ray F., 43
Kirkham, Fenella, 291, 405
Kisiel, Walter, 291
Knoefler, Ralf, 575
Kobashi, Gen, 653
Kobayashi, Takao, 645
Kohli, Manish, 301
Kondo, Kiyotaro, 653
Kosch, Andrea, 227
Kostka, Heike, 575
Kroner, Barbara L., 69
Krouwer, Hendrikus G., 309
Kudryk, Bohdan, 297
Kuhle, Stefan, 329, 377
Kuhlisch, Eberhard, 575
Kupferminc, Michael J., 185
Kurnik, Karin, 405
Kwaan, Hau C., 283, 433, 451, 489, 529, 535

Lafeber, Floris P.J.G., 37
Lanir, Naomi, 175
Lethagen, Stefan, 101
Levine, Mark, S1:1, S1:9
Linkins, Lori-Ann, 619
Ljung, Rolf, 31
Ludwig, Kathrin, 575

Mac Gillavry, Melvin R., 219
Maki, Mashiro, 645
Male, Christoph, 329, 377
Mammen, Eberhard F., 1, 237, 323, 325, 543
Manco-Johnson, Marilyn, 349, 585
Mariani, Guglielmo, 69
Massicotte, M. Patricia, 557
Mehta, Jayesh, 467
Mehta, Paulette, 275, 301
Meiselman, Herbert J., 435
Michelson, Alan D., 363
Michiels, Jan J., 5, 205
Minakami, Hisanori, 639
Mitchell, Lesley, 329, 377
Monagle, Paul, 547
Morikawa, Mamoru, 639
Muszbek, Laszlo, 171

Nakabayashi, Masao, 645
Nowak-Göttl, Ulrike, 227, 405
Nuss, Rachelle, 43

Ohta, Kaori, 653
Ornstein, Deborah L., 259

Pabinger, Ingrid, 633
Pagnan, Antonio, S1:3
Palumbo, Manlio, 661
Parmar, Simrit, 283
Peake, Ian R., 23
Petäjä, Jari, 349
Peters, Marjolein, 391
Piccioli, Andrea, S1:3
Pollow, Kunhard, 499
Price, Victoria, 557
Prandoni, Paolo, S1:3
Prins, Martin H., 219

Rampling, Michael W., 459
Rand, Margaret L., 363
Rand, Scott D., 309
Revel-Vilk, Shoshana, 425
Riske, Brenda, 585
Rodriguez-Merchan, E. Carlos, 87, 97
Roosendaal, Goris, 37
Rosenkrantz, Ted S., 515


Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Rózanska-Kudelska, Malgorzata, 317

Saghafifar, Fariba, 275
Sakuragi, Noriaki, 639
Sameshima, Hiroshi, 645
Sakurai, Shumpei, 529
Samama, Meyer-Michel, 131
Scharf, Rüdiger E., 143
Schlegel, Nicole, 227
Schmainda, Kathleen M., 309
Schmidt, Barbara, 323
Schulman, Sam, S1:33
Shalev, Eliezer, 213
Shimada, Shigeki, 639
Siegert, Gabriele, 575
Sierko, Ewa, 291, 317
Singhal, Seema, 467
Siragusa, Sergio, 69
Sissi, Claudia, 661
Splichal, James E., 259
Stamm, Jason A., 259
Sträter, Ronald, 405
Sutor, Anton H., 373
Suttorp, Meinolf, 575
Suzuki, Shigenori, 639

Tamashiro, Hidehiko, 653
Tavoni, Antonio, 473
Tedgård, Ulf, 31
Torri, Giangiacomo, 661
Toshihiko Terao, 645
Thompson, Arthur R., 11
Tricot, Guido, 275
Tsai, Han-Mou, 479

van den Berg, H. Marijke, 49
van Ommen, C. Heleen, 391
von Tempelhoff, Georg-Friedrich, 499
Voorberg, Jan, 61

Wang, Jun, 283, 451, 529
Weiner, Zeev, 213
Weitz, Jeffrey I., 619
White, Kami, 235
Wojtukiewicz, Marek Z., 291, 317

Yamada, Hideto, 639
Younis, Johnny S., 213

Zacharski, Leo R., 239, 291, 317
Zangari, Maurizio, 275
Zarkovic, Mirjana, 535
Zimnoch, Lech, 291, 317
Zotz, Rainer B., 143

# Subject Index

VOLUME 29, 2003

*Note: Numbers preceded by S1 indicate pages in Volume 29, Supplement 1.*


A

Abruptio placentae, thrombophilia and, 185–194
aCLβ2GPI syndrome, in pregnancy, 639–643
Activated protein C, recombinant, 624
Activated protein C resistance, in multiple myeloma, 275–281
Acute coronary syndromes, new anticoagulants for, 623–624, 629
ADAMTS13, cleavage of von Willebrand factor by, shear stress and, 479–488
Adeno-associated virus (AAV), as vector for gene transfer, in hemophilia A, 107–119
Aging, and venous thromboembolism, S1:19
Air travel, and venous thromboembolism, S1:27
Andrew, Maureen, 321–323
Anemia, in cancer, hyperviscosity and, 499–513
Angiogenesis
  in gastric cancer, 291–299
  neoplastic, magnetic resonance imaging of, 309–315
  in prostate cancer, 301–308
  in tumors, rheological changes and, 489–497
Anticardiolipin antibodies, in pregnancy, 195–203, 639–643
Anticoagulant mechanisms
  during childhood, 329–337
  in human placenta, 175–183
Anticoagulant therapy
  in cancer
    for DVT prevention and treatment, 247–258, S1:9–11
    for hyperviscosity, 499, 509
    impact on outcome and survival, S1:13–15
    for modulation of malignancy growth, 237–238, 239–246, 317–320
    and risk of recurrent thromboembolism, S1:3–8
    for secondary prevention, S1:9–11
  for infants and children, 227–233, 425–432
    for arterial ischemic stroke, 405–414, 571
    for arterial thrombosis, 561–562
    in heart disease, 547, 551–552
    for venous thromboembolism, 391–403
  new, 619–631
    future directions for, 628–629
    pathways for, 620–621
    targets for, 621–628
  in pregnancy, 633–638
    for antiphospholipid syndrome, 195–203, 633, 636
    for arterial thrombosis, 155–163
    for essential thrombocythemia, 205–212
    management at time of delivery, 636
    and prevention of fetal loss, 165–170, 633, 636
    for venous thromboembolic disease, 131–141, 143–153, 633–638
    for women with inherited thrombophilia, 131–141, 185–194
  for primary prevention, S1:27
  "real world" use of, S1:23–31
  for secondary prevention, S1:27–28
  targets of, factor Xa *versus* factor IIa, S1:33–36, S1:37
Anti-D immunoglobulin, for ITP in children, 600, 612–613
Antiphospholipid syndrome, 195–203, 633, 636, 639–643
Antithrombin, in coagulation regulation, 620
Antithrombin concentrate, for severe preeclampsia, 645–652
Antithrombin-protease interactions of heparin, sulfation patterns and, 661–670
Apheresis, for hyperviscosity, 535–542
  in cryoglobulinemia, 473, 476–477, 535, 538–539
  in plasma cell dyscrasias, 467, 469–470, 535, 538–539
Argatroban, 626
Arterial ischemic stroke
  in neonates, infants, and children, 405–414
    overview of current approaches in, 567–573
  perinatal and neonatal, prothrombotic disorders and, 415–424
Arterial thromboembolism
  in children, 557–565
  formation of, 620
  new anticoagulants for, 619–631
Arterial thrombosis
  in pregnancy, prevention and treatment of, 155–163
  von Willebrand factor and shear stress in, 479, 487
Arthrodesis, for hemophilic arthropathy, 87–95
Arthropathy, hemophilic
  in children, 589–591
  mechanisms and biochemistry of, 37–42
  modern management of, 1–3
  orthopedic management of, 87–95, 590–591
  prevention of, 5–10, 49–54, 97–100, 589–590
  radiological evaluation of, 43–48
Ascorbic acid, for ITP in children, 601
Aspirin
  for infants and children
    for arterial ischemic stroke, 405–414, 571
    with congenital heart disease, 551–552
  in pregnancy
    for antiphospholipid syndrome, 195–203, 633, 636
    for essential thrombocythemia, 205–212
Atrial fibrillation, ximelagatran for, 627–628, 628–629
Azathioprine, for ITP in children, 601


Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

B
BDD (β-domain-deleted) FVIII, 588
Bivalirudin, 625–626, 629
Blalock-Taussig shunts, thrombotic occlusion of, 551, 560
Bleeding frequency, in hemophilia, prophylactic therapy and, 49–54
Blood hemodynamics, 435–450
Blood rheology, 435–450
  in cancer, 489–497, 499–513
  in polycythemia vera, 451–458
  and thromboembolism in heart disease, 529–534
Blood viscosity, 435–450. *See also* Hyperviscosity
Bone marrow aspiration, in acute ITP in children, 605, 614
Brain tumors, angiogenesis of, magnetic resonance imaging of, 309–315
Bypassing agents, for bleeding hemophilic patients with inhibitors, 77–85

C
Cancer
  angiogenesis in, magnetic resonance imaging of, 309–315
  anticoagulant therapy in, impact on outcome and survival, S1:13–15
  coagulation biology of, 237–238
  deep venous thrombosis in, importance, treatment, and management of, 247–258
  hyperviscosity in, 499–513
  laryngeal, fibrinolytic pathway components in, 317–320
  malignancies in, as solid-phase coagulopathies, 239–246
  multiple myeloma
    blood coagulation mechanism in, 275–281
    hyperviscosity in, 467–471, 535, 538–539
  pediatric, TAFI antigen levels in, TAFI gene polymorphisms and, 575–585
  prostate, coagulation and fibrinolytic system in, 301–308
  recurrent thromboembolism in
    incidence of and risk factors for, S1:3–8
    secondary prevention of, S1:9–11
  rheological variables in, 489–497, 499–513
  statin therapy in, 259–274
  thrombosis in
    blood rheology and, 499, 504–506
    pathogenesis of, 283–290
  tumor microenvironment in, 489–497
Cardiac catheterization, and thrombosis in children, 547, 549–551, 559
Carriers of hemophilia gene, genetic counseling for, 31–36
Catheter-related thrombosis, in children, 377–389, 391–403, 547, 549–551, 558–559
Chemotherapy
  blood rheology during, 506–508
  and hypercoagulability in multiple myeloma, 275–281
Children
  anticoagulation therapy in, 425–432
    in cardiac patients, 547, 551–552
  arterial ischemic stroke in, 405–414
    overview of current approaches in, 567–573
  arterial thromboembolism in, 557–565
    etiology of, 558–561
    treatment of, 561–562
  catheter-related thromboembolism in, 377–389, 391–403, 547, 549–551, 558–559
  congenital hyperlipidemia in, 547, 548, 561
  fibrinolytic system in, 339–347
  hemophilic
    advances in care for, 585–594
    collaborations for research and care advances for, 591
    in developing countries, expanding care to, 591
    gene therapy for, 591
    home therapy for, 587–588
    immune tolerance in, 590
    orthopedic interventions for joint disease in, 590–591
    prophylaxis in, 49–54, 589–590
    specialized centers for, 586–587
  hemostasis in, 325–327, 329–337, 543–545
  idiopathic thrombocytopenic purpura in
    acute, 605–617
    mild chronic, 596–597
    moderately severe chronic, 597
    severe chronic, 595–603
  Kawasaki's disease in, 547, 548–549, 560
  myocardial infarction in, 547, 548, 549
  TAFI antigen levels in, *TAFI* gene polymorphisms and, 575–585
  Takayasu's arteritis in, 560
  thrombosis in, 325–327, 543–545
    with heart disease, 547–555, 560–561
    iatrogenic, 547, 549–551
  venous thromboembolism in, 391–403
    diagnosis of, 377–389
    protein C pathway and, 349–361
Clotting factors. *See also specific factors*
  during pregnancy, 125–130
    deficiencies of, and pregnancy loss, 171–174
Coagulation
  in cancer
    and deep venous thrombosis, 247–258
    in gastric cancer, 291–299
    implications for etiology, pathogenesis, and treatment, 239–246
    and increased risk of thrombosis, 283–290
    in laryngeal cancer, 317–320
    and modulation of malignancy growth, 237–238
    in multiple myeloma, 275–281
    in prostate cancer, 301–308
    statins and, 259–274
  in hemophilia, 586
  initiation of, inhibitors of, 621–622
  propagation of, inhibitors of, 622–624
  regulation of, 620
Coagulopathy, solid-phase, malignancy as, 239–246
Colchicine, for ITP in children, 601
Computed tomography, of arterial ischemic stroke, in infants and children, 571
Congenital heart disease (CHD)
  and arterial ischemic stroke, 567, 570–571
  primary anticoagulant prophylaxis in children with, 551–552
  thrombosis in, 547–555, 560–561
Congenital hyperlipidemia, in children, 547, 548, 561
Connective tissue disease, hyperviscosity in, 459–466

Coronary artery aneurysm, in children, with Kawasaki's disease, 547, 548–549
Corticosteroids, for ITP in children, 600, 605, 609–610, 613
Cryoglobulinemia, hyperviscosity in, 473–477
  plasmapheresis for, 473, 476–477, 535, 538–539
Cyclophosphamide, for ITP in children, 601
Cyclosporine, for ITP in children, 601
Cytapheresis, 535–542

D
Danazol, for ITP in children, 601
Dapsone, for ITP in children, 601
DDAVP, for hemophilia, 101–106, 589
Deep venous thrombosis
  cancer-related
    blood rheology and, 504–506
    importance, treatment, and management of, 247–258
    in multiple myeloma, 275–281
    recurrent, incidence of and risk factors for, S1:3–8
    secondary prevention of, S1:9–11
  in medical patients, S1:17–21
  prevention of
    primary, S1:27
    "real world" strategies for, S1:23–31
    secondary, S1:27–28
  treatment in high-risk groups, S1:1
Desmopressin, for hemophilia, 101–106, 589
Developing countries, expanding care for hemophilic children in, 591
Developmental hemostasis, 329–337
Dexamethasone, for ITP in children, 600
DPC 906, 623–624
Drotrecogin alfa, 624
DX-9065a, 623–624, 629

E
Echocardiography, spontaneous echo contrast in, 529–534
Elderly, venous thromboembolism in, S1:19
Endovascular stents, thrombotic occlusion of, 551–552
Epsilon-aminocaproic acid, for hemophilia, 589
Erythrocytapheresis, 535–542
Erythrocyte aggregation, 435–450. *See also* Hyperviscosity
  in polycythemia vera, 451–458
  and thromboembolism in heart disease, 529–534
Erythrocyte deformability, 435–450
Essential thrombocythemia
  hyperviscosity in, apheresis for, 535, 540–541
  in pregnancy, 159, 205–212

F
Factor concentrates, for hemophilia. *See* Factor IX therapy; Factor VIII therapy
Factor IIa
  recombinant, 77–85, 87–95
  as therapeutic target of anticoagulation, *versus* factor Xa, 37, S1:33–36
Factor IXa inhibitors, 622
Factor IX deficiency, 586
Factor IX gene, as therapeutic target, in hemophilia, 107–119
Factor IX therapy
  inhibitory antibodies to, treatment of bleeding patient with, 77–85
  safe and effective, development of, 588–589
Factor VIIa
  active-site blocked (FVIIai), 621, 622
  recombinant, for hemophilia, 589
Factor VIII, plasma concentrations of, desmopressin therapy and, 101–106
Factor VIII deficiency, 586
Factor VIII gene
  mutations of
    and hemophilia A, 23–30
    identification of and counseling for carriers of, 31–36
    and inhibitor antibody formation, 23–30
  structure and expression of, 11–22
  as therapeutic target, in hemophilia, 107–119
Factor VIII protein, domain structure and function of, 11–22
Factor VIII therapy
  inhibitor antibodies to
    bleeding patient with, treatment of, 77–85
    in children, 590
    development of, immunobiology of, 61–68
    eradication of, immune tolerance induction for, 69–75, 590
    genetic mutation types and, 23–30
    modern management of, 1–3
    preventing formation of, 5–10
  parental or self-infusion for home use of, 587–588
  prophylactic
    for arthropathy prevention, 5–10, 49–54, 589–590
    dose, start, and duration of, 49–54
    experience in Europe and United States with, 49–54
    for hemophilic children, 589–590
    orthopedic outcome studies and cost issues of, 55–60
  safe and effective, development of, 588–589
Factor V Leiden, in infants and children, 349–361
Factor X, intrinsic, activation of, 11–22
Factor Xa, as therapeutic target of anticoagulation, *versus* factor IIa, 37, S1:33–36
Factor Xa inhibitors, 622–624, 628–629
Factor XIII deficiency, and pregnancy loss, 171–174
Familial hypercholesterolemia, in children, 547, 548, 561
Femoral artery thrombosis, pediatric cardiac catheterization and, 549–550
Fetal loss
  antiphospholipid syndrome and, 195–203, 633, 636, 639–643
  coagulation factor deficiencies and, 171–174
  prevention of, anticoagulant therapy and, 165–170, 633, 636
  thrombophilia and, 165–170, 185–194
Fibrin formation, inhibitors of, 624–628
Fibrinogen
  deficiency, and pregnancy loss, 171–174
  elevated, and thromboembolism in heart disease, 529–534
Fibrinolytic inhibitors, for hemophilia, 589
Fibrinolytic system
  in cancer, 283–290
    gastric, 291–299
    laryngeal, 317–320

Fibrinolytic system, in cancer *(continued)*
prostate, 301–308
in children, 339–347
*TAFI* gene polymorphisms and, 575–585
in human placenta, 175–183
during pregnancy, 125–130
Fondaparinux, 623–624, 628–629
Fontan operation, thrombosis with, 551, 560

G
Gastric cancer, tissue factor-dependent coagulation activation and impaired fibrinolysis in, 291–299
Gene therapy, for hemophilia, 107–119, 591
Genetic counseling, for hemophilia carriers, 31–36
Gene transfer, for hemophilia A, 107–119
Genotype-phenotype relationships, in hemophilia A, 23–30
Glioblastoma multiforme, angiogenesis of, imaging of, 309–315
Glutathione S-transferase P1 gene, and hypertension in pregnancy, 653–659
Glycosaminoglycan sulfation patterns, 661–670

H
Heart disease
pediatric
and arterial ischemic stroke, 567, 570–571
primary anticoagulant prophylaxis in, 551–552
thrombosis in, 547–555, 560–561
rheological complications and thromboembolism in, 529–534
Heart valves, prosthetic
children with, thrombosis risk and prevention in, 552
new anticoagulant therapy for patients with, 629
pregnant women with
anticoagulant therapy for, 155–163, 636–637
arterial thrombosis in, prevention and treatment of, 155–163
Hemarthrosis, in hemophilia. *See* Arthropathy, hemophilic
Hematocrit, in polycythemia, 451–458, 515–527
Hemodynamics, 435–450
Hemophilia
arthropathies in, 1–3
mechanisms and biochemistry of, 37–42
orthopedic management of, 87–95
prevention of, 5–10, 49–54, 97–100
radiological evaluation of, 43–48
basic mechanisms in, 586
carriers of, genetic counseling for, 31–36
children with
advances in care for, 585–594
collaborations for research and care advances for, 591
in developing countries, expanding care to, 591
gene therapy for, 591
immune tolerance in, 590
prophylaxis in, 49–54, 589–590
specialized centers for, 586–587
gene transfer for, 107–119
health without arthropathy in, 5–10
musculoskeletal complications of, management of, 87–95
prophylaxis in, 5–10, 49–54, 589–590
orthopedic outcome studies and cost issues of, 55–60
radionuclide synovectomy in, 97–100, 590
Hemophilia A. *See also* Hemophilia
genotype-phenotype relationships in, 23–30
inhibitor formation in, 1–3
bleeding patient with, treatment of, 77–85
factor VIII mutation types and, 23–30
immune tolerance induction for eradicating, 69–75
immunobiology of, 61–68
prevention of, 5–10
mild, desmopressin for, 101–106
modern management of, 1–3
molecular basis of, 23–30
Hemorrhagic disease of newborn, prevention of, vitamin K prophylaxis for, 373–376
Hemostasis
developmental, 329–337
in human placenta, 175–183
in normal pregnancy and puerperium, 125–130
pediatric, 325–327, 329–337, 543–545
Heparin
antithrombin-protease interactions of, sulfation patterns and, 661–670
in cancer
for DVT prevention and treatment, 247–258, S1:9–11
for hyperviscosity, 509
impact on outcome and survival, S1:13–15
for modulation of malignancy growth, 237–238, 317–320
and risk of recurrent thromboembolism, S1:3–8
for secondary prevention, S1:9–11
in infants and children, 425–432
for arterial ischemic stroke, 405–414, 571
for arterial thrombosis, 561–562
with congenital heart disease, 551–552
for venous thromboembolism, 391–403
*versus* new anticoagulants, 619–631
in pregnancy, 633–638
for antiphospholipid syndrome, 195–203, 633, 636
for arterial thrombosis, 155–163
for essential thrombocythemia, 205–212
and prevention of fetal loss, 165–170, 633, 636
for venous thromboembolic disease, 131–141, 143–153, 633–638
for women with inherited thrombophilia, 131–141, 185–194
for primary prevention, S1:27
Heparin-induced thrombocytopenia, 635
Hepatic artery occlusion, in children, 560–561
Hirudin, 625
Home therapy, for hemophilia, 587–588
Hypercoagulability
in cancer
and deep venous thrombosis, 247–258
in multiple myeloma, 275–281
pathogenesis of, 283–290
of prostate, 301–308
in normal pregnancy, 125–130
Hypergammaglobulinemia, and hyperviscosity, 467–471
Hyperleukocytosis
hyperviscosity in, 459–466
leukapheresis for, 535, 539–540

Hyperlipidemia, congenital, in children, 547, 548, 561
Hyperviscosity
  apheresis for correction of, 535–542
  in cancer, 499–513
  as complication in variety of disorders, 459–466
  in cryoglobulinemia, 473–477
  in plasma cell dyscrasias, 467–471, 535, 538–539
  and polycythemia in newborns, 515–527
  in polycythemia vera and other red blood cell abnormalities, 451–458
  syndromes of, 433
  and thromboembolism in heart disease, 529–534

I
Iatrogenic thrombosis, in children with cardiac disease, 547, 549–551
Idiopathic thrombocytopenic purpura, in children
  acute, 605–617
    emergency treatment of, 613
    hospitalization for, 614
    natural history of, 608
    therapeutic options in, 609–614
    treatment *versus* nontreatment in, 608–609
  chronic
    bleeding risk and treatment response in, assessment of, 598–599
    definition of severity based on platelet count, 596–598
    disease progression in, 598
    general management principles in, 599
    mild, 596–597
    moderately severe, 597
    severe, 595–603
    treatment of, 600–601
Idraparinux, 623–624
Immune tolerance induction (ITI), in hemophilia, 69–75, 590
Immunoglobulin G, intravenous (IVIG), for ITP in children, 600, 605, 610–612
Immunoglobulin G antibodies, in hemophilia. *See* Inhibitor development
Infants
  arterial ischemic stroke in, 405–414
    overview of current approaches in, 567–573
    prothrombotic disorders and, 415–424
  fibrinolytic system in, 339–347
  platelet function in, 363–371
  polycythemia and hyperviscosity in, 515–527
  thromboembolism in, 227–233
    diagnosis of, 377–389
    protein C pathway and, 349–361
  umbilical artery catheterization in, and thrombosis, 558–559
  vitamin K prophylaxis for, 373–376
Inhibitor(s), during pregnancy, 125–130
Inhibitor development, in hemophilia
  bleeding patient with, treatment of, 77–85
  in children, 590
  factor VIII mutation types and, 23–30
  immune tolerance induction for eradicating, 69–75, 590
  immunobiology of, 61–68
  modern management of, 1–3
  prevention of, 5–10
Interferon alfa, for ITP in children, 601
Intracranial hemorrhage, in acute ITP in children, 605, 608–609
Intrauterine growth retardation (IUGR)
  anticardiolipin antibodies and, 639–643
  thrombophilia and, 185–194
Inversions, of factor VIII gene, 23–30
Ischemic stroke
  in neonates, infants, and children, 405–414
    overview of current approaches in, 567–573
  perinatal and neonatal, prothrombotic disorders and, 415–424
IVIG, for ITP in children, 600, 605, 610–612

J
Joint hemorrhage and damage, in hemophilia. *See* Arthropathy, hemophilic
Joint replacement, for hemophilic arthropathy, 87–95

K
Kawasaki's disease, thrombosis in, 547, 548–549, 560
Kidney transplantation, and renal artery thrombosis, in children, 561

L
Laryngeal cancer, fibrinolytic pathway components in, 317–320
Leukapheresis, 462–463, 535–542
Leukemia, hyperviscosity in, 459–465
  apheresis for, 462–463, 535, 539–541
Leukostasis, 459–466
Liver transplantation, and hepatic artery occlusion, in children, 560–561
Low-molecular-weight heparin. *See also* Heparin
  antithrombin-protease interactions of, sulfation patterns and, 661–670
  in cancer
    impact on outcome and survival, S1:13–15
    for secondary prevention of DVT, S1:9–11
Lupus anticoagulants, in pregnancy, 195–203

M
Macroglobulinemia, hyperviscosity in, 467–471
  plasmapheresis for, 467, 469–470, 535, 538–539
Magnetic resonance imaging (MRI)
  of arterial ischemic stroke, in infants and children, 405–414, 571
  of hemophilic arthropathy, 43–48
  of neoplastic angiogenesis, 309–315
  of venous thromboembolism, in children, 377–389
Malignancy. *See also* Cancer
  as solid-phase coagulopathy, 239–246
Malignant growth, modulation by coagulation mechanism and anticoagulants, 237–238
Medical patients, venous thromboembolism in, S1:17–21
Methylprednisolone, for ITP in children, 600, 609–610, 613
Microenvironment, tumor, 489–497
Miscarriage
  antiphospholipid syndrome and, 195–203, 633, 636, 639–643

Miscarriage *(continued)*
coagulation factor deficiencies and, 171–174
prevention of, anticoagulant therapy and, 165–170, 633, 636
thrombophilia and, 165–170, 185–194
Mixed cryoglobulinemia, hyperviscosity in, 473–477
Monoclonal cryoglobulinemia, hyperviscosity in, 473–477
Multiple myeloma
blood coagulation mechanism in, 275–281
hyperviscosity in, 467–471
plasmapheresis for, 467, 469–470, 535, 538–539
Musculoskeletal complications. *See also* Arthropathy, hemophilic
of hemophilia, management of, 87–95
Mycophenolate mofetil, for ITP in children, 601
Myeloma. *See* Multiple myeloma
Myocardial infarction
in children, 547, 548, 549
in pregnancy, prevention and treatment of, 155–163

N
Nematode anticoagulant peptide, 621–622, 629
Neonates
arterial ischemic stroke in, 405–414
overview of current approaches in, 567–573
prothrombotic disorders and, 415–424
fibrinolytic system in, 339–347
platelet function in, 363–371
polycythemia and hyperviscosity in, 515–527
thromboembolism in, 227–233
diagnosis of, 377–389
protein C pathway and, 349–361
umbilical artery catheterization in, and thrombosis, 558–559
vitamin K prophylaxis for, 373–376
Nephrotic syndrome, venous thromboembolism in, S1:17, S1:20

O
Oral anticoagulation, for secondary prevention of DVT, in cancer patients, S1:9–11
Oral contraceptives, and venous thrombosis in women with inherited thrombophilia, 219–226
Orthopedic outcomes, of prophylaxis in hemophilia, 55–60
Orthopedic procedures, for hemophilic arthropathy, 87–95, 590–591

P
Paraproteinemias, hyperviscosity in, plasmapheresis for, 535, 538–539
Parenteral infusion, of factor concentrate, 587–588
Pediatric thrombosis and hemostasis, 325–327, 543–545. *See also* Children; Infants
Perinatal stroke, prothrombotic disorders and, 415–424
Peripheral arterial catheterization, and thrombosis in children, 558
Placenta
abnormalities or disorders of, thrombophilia and, 165–170, 185–194, 213–217
procoagulant and anticoagulant mechanisms of, 175–183
Placental circulation, in thrombophilic women, 213–217
Plasma cell dyscrasias, hyperviscosity in, 467–471
apheresis for, 467, 469–470, 535, 538–539
Plasmapheresis, for hyperviscosity, 535–542
in cryoglobulinemia, 473, 476–477, 535, 538–539
in plasma cell dyscrasias, 467, 469–470, 535, 538–539
Platelet count, in ITP in children, 596–598, 600, 605
Platelet function
neonatal, 363–371
during pregnancy, 125–130
Plateletpheresis, 535–542
Platelet transfusion, for acute ITP in children, 605, 613
Polycythemia, in newborns, hyperviscosity and, 515–527
Polycythemia vera, hyperviscosity in, 451–458
apheresis for, 535, 540–541
Porcine factor VIII, for bleeding hemophilic patients with inhibitors, 77, 82–83
P32 radiosynoviorthesis, 590
Prednisone, for ITP in children, 600, 605, 609–610
Preeclampsia
anticoagulant therapy for, 636
glutathione S-transferase P1 gene and, 653–659
and perinatal and neonatal stroke, 415–424
severe, antithrombin concentrate for, 645–652
thrombophilia and, 165–170, 185–194
Pregnancy
acquired thrombophilia in, 205–212
anticardiolipin antibodies in, 195–203, 639–643
anticoagulation during, 633–638
antiphospholipid syndrome in, 195–203, 633, 636, 639–643
arterial thrombosis in, prevention and treatment of, 155–163
hypertension in. *See also* Preeclampsia
glutathione S-transferase P1 gene and, 653–659
normal, hemostasis during, 125–130
placental disorders in, thrombophilia and, 165–170, 185–194, 213–217
vascular complications in, thrombophilia and, 185–194
venous thromboembolism in, S1:26
anticoagulation for, 131–141, 143–153, 633–638
inherited thrombophilia and, 131–141
prediction, prevention, and treatment of, 143–153
Pregnancy loss
antiphospholipid syndrome and, 195–203, 633, 636, 639–643
coagulation factor deficiencies and, 171–174
prevention of, anticoagulant therapy and, 165–170, 633, 636
thrombophilia and, 165–170, 185–194
Procoagulant mechanisms
in cancer, 283–290
during childhood, 329–337
in human placenta, 175–183
Prostate cancer, coagulation and fibrinolytic system in, 301–308
Prosthetic heart valves
children with, thrombosis risk and prevention in, 552
new anticoagulant therapy for patients with, 629
pregnant women with
anticoagulant therapy for, 155–163, 636–637
arterial thrombosis in, prevention and treatment of, 155–163

Protein C concentrates, 624
Protein C pathway
in coagulation regulation, 620
in infants and children, 349–361
Protein S, in infants and children, 349–361
Proteolysis, of von Willebrand factor, shear stress and, 479–488
Prothrombin complex concentrate (PCC), for bleeding hemophilic patients with inhibitors, 77, 81–82
Puerperium, normal, hemostasis during, 125–130
Pulmonary embolism (PE)
cancer-related, 247–258
in infants and children, 391–403
diagnosis of, 377–389
in medical patients, S1:17–21
prevention of, "real world" strategies for, S1:23–31
"Pulseless disease," 559–560

R
Radiological evaluation, of hemophilic arthropathy, 43–48
Radionuclide synovectomy (radiosynoviorthesis), in hemophilia, 97–100, 590
Red blood cell aggregation, 435–450. *See also* Hyperviscosity
in polycythemia vera, 451–458
and thromboembolism in heart disease, 529–534
Red blood cell deformability, 435–450
Relative cerebral blood volume (rCBV) mapping, in neoplastic angiogenesis, 309–315
Renal artery thrombosis, in children, 561
Restriction fragment length polymorphisms (RFLP), of hemophilia gene, 31–36
Retinoic acid syndrome, hyperviscosity in, 459, 463
Retroviral vector, for gene transfer, in hemophilia A, 107–119
Rheology of blood, 435–450
in cancer, 489–497, 499–513
in polycythemia vera, 451–458
and thromboembolism in heart disease, 529–534
Rheumatoid arthritis, hyperviscosity in, 459, 463–464
Rituximab, for ITP in children, 601
Rouleaux formation, 459, 466

S
Self-infusion, of factor concentrate, 587–588
Sepsis, in infants and children, protein C pathway and, 349–361
Shear stress, and von Willebrand factor, 479–488
Sickle cell disease
arterial thrombosis in pregnant women with, prevention and treatment of, 155–163
hyperviscosity in, apheresis for, 535, 541
Sinovenous thrombosis, perinatal and neonatal, prothrombotic disorders and, 415–424
Solid-phase coagulopathy, malignancy as, 239–246
Soluble thrombomodulin, 624
Splenectomy, for ITP in children, 595, 599, 600–601, 605
Spontaneous echo contrast (SEC), 529–534
Statins, antithrombotic and antineoplastic effects of, 259–274
Stroke
in neonates, infants, and children, 405–414
overview of current approaches in, 567–573
perinatal and neonatal, prothrombotic disorders and, 415–424
in pregnancy, prevention and treatment of, 155–163
Sulfation patterns, in heparin therapy, effect on antithrombin-protease interactions, 661–670
Supportive care, for arterial ischemic stroke, in infants and children, 571–572
Synovectomy, for hemophilic synovitis, in children, 590–591
Synovitis, hemophilic, 37–42
in children, interventions for, 590–591
orthopedic management of, 87–95, 590–591
radiological evaluation of, 43–48
radionuclide synovectomy for, 97–100, 590

T
*TAFI* gene, and TAFI antigen levels, in healthy children and pediatric cancer patients, 575–585
Takayasu's arteritis, 559–560
Thalidomide, and hypercoagulability in multiple myeloma, 275–281
Thrombin activatable fibrinolysis inhibitor (*TAFI*) gene polymorphisms, and TAFI antigen levels, in healthy children and pediatric cancer patients, 575–585
Thrombin inhibitors, 624–628, S1:33–37
Thrombocythemia, essential
hyperviscosity in, apheresis for, 535, 540–541
in pregnancy, 159, 205–212
Thrombocytopenia. *See also* Idiopathic thrombocytopenic purpura; Thrombotic thrombocytopenic purpura
heparin-induced, 635
Thromboembolism
aging and, S1:19
in cancer, S1:19–20
anticoagulation for, 131–141, 143–153, 633–638
blood rheology and, 499, 504–506
in gastric cancer, 291–299
importance, treatment, and management of, 247–258
in multiple myeloma, 275–281
pathogenesis of, 283–290
recurrent, incidence of and risk factors for, S1:3–8
secondary prevention of, S1:9–11
statins and, 259–274
formation of, 620
in heart disease, rheological abnormalities and, 529–534
in infants and children, 227–233, 391–403
anticoagulation therapy for, 425–432
arterial, 557–565
diagnosis of, 377–389
with heart disease, 547–555
iatrogenic, 547, 549–551
protein C pathway and, 349–361
in medical patients, S1:17–21
neonatal, 227–233, 349–361
new anticoagulants for, 619–631
oral contraceptive use in thrombophilic women and, 219–226
in pregnancy
venous, 131–141, 143–153, 633–638, S1:26
prevention of
primary, S1:27
"real world" strategies for, S1:23–31
secondary, S1:27–28
Thrombogenesis, 620

Thrombolytic therapy, for children, 561–562
Thrombomodulin, soluble, 624
Thrombophilia
  acquired, in pregnancy, 205–212
  and fetal loss, 165–170, 185–194
  inherited
    and gestational vascular complications, 185–194
    and gestational venous thromboembolism, 131–141
    oral contraceptive use in women with, 219–226
  and placental circulation, 213–217
  and venous thromboembolism, S1:26–27
  women's issues in, 121–123
Thrombosis. *See also* Thromboembolism
  arterial
    in pregnancy, prevention and treatment of, 155–163
    von Willebrand factor and shear stress in, 479, 487
  deep venous. *See* Deep venous thrombosis
  pediatric, 325–327, 543–545
    in cardiac patients, 547–555
    iatrogenic, 547, 549–551
  in polycythemia vera, hyperviscosity and, 451–458
  in pregnancy
    arterial, prevention and treatment of, 155–163
Thrombotic thrombocytopenic purpura, von Willebrand factor and shear stress in, 479, 486–487
Tissue factor, and coagulation in cancer, 283–290
  in gastric cancer, 291–299
  in prostate cancer, 301–308
Tissue factor pathway inhibitor, 620, 621
Tissue plasminogen activator, for infants and children
  for arterial ischemic stroke, 405–414
  for arterial thrombosis, 561–562
Tolerance induction, in hemophilia, 69–75, 590
Tranexamic acid, for hemophilia, 589
Tumor interstitial fluid, 489–497
Tumor microenvironment, 489–497

U

Ultrasound, of venous thromboembolism in children, 377–389, 391–403
Umbilical artery catheterization, and thrombosis, 558–559
Unfractionated heparin. *See* Heparin

V

Vascular endothelial growth factor (VEGF), in tumor microenvironment, 489–497
Venography, of venous thromboembolism, in children, 377–389
Venous thromboembolism
  aging and, S1:19
  cancer-related, S1:19–20
    importance, treatment, and management of, 247–258
    in multiple myeloma, 275–281
    recurrent, incidence of and risk factors for, S1:3–8
    secondary prevention of, S1:9–11
  formation of, 620
  in infants and children, 391–403
    anticoagulation therapy for, 425–432
    diagnosis of, 377–389
    with heart disease, 548
    protein C pathway and, 349–361
  in medical patients, S1:17–21
  new anticoagulants for, 619–631
  oral contraceptive use in thrombophilic women and, 219–226
  in pregnancy, S1:26
    anticoagulation for, 131–141, 143–153, 633–638
    inherited thrombophilia and, 131–141
    prediction, prevention, and treatment of, 143–153
  prevention of
    new anticoagulants for, 623, 626–628
    primary, S1:27
    "real world" strategies for, S1:23–31
    secondary, S1:27–28
  treatment in high-risk groups, S1:1
Vinca alkaloids, for ITP in children, 601
Viscosity, of blood, 435–450. *See also* Hyperviscosity
Vitamin K-deficiency bleeding (VKDB), in infants, prevention of, 373–376
Vitamin K prophylaxis, for infants, 373–376
von Willebrand factor (vWF)
  in neonates, 363–371
  plasma concentrations of, desmopressin therapy and, 101–106
  shear stress and, 479–488

W

Waldenström's macroglobulinemia, hyperviscosity in, 467–471
  plasmapheresis for, 467, 469–470, 535, 538–539
Warfarin
  in cancer
    for deep venous thrombosis, 247–258
    and risk of recurrent thromboembolism, S1:3–8
  in children, 425–432
    for arterial ischemic stroke, 405–414, 571
    with congenital heart disease, 551–552
  *versus* new anticoagulants, 619–631
  for secondary prevention, S1:27–28
Women's issues. *See also* Oral contraceptives; Pregnancy; Pregnancy loss
  in thrombophilia, 121–123
World Federation of Hemophilia, 591

X

Ximelagatran, 626–628, 628–629